Terms: = Lymphoma AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
235 results:
1. Hairy cell leukemia 2024: Update on diagnosis, risk-stratification, and treatment-Annual updates in hematological malignancies.
Troussard X; Maître E; Paillassa J
Am J Hematol; 2024 Apr; 99(4):679-696. PubMed ID: 38440808
[TBL] [Abstract] [Full Text] [Related]
2. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Kim JL; Gerrie AS; Savage KJ; Villa D; Scott D; Craig JW; Farinha P; Skinnider B; Slack G; Connors JM; Sehn LH; Venner C; Freeman CL
Leuk Lymphoma; 2024 Mar; 65(3):346-352. PubMed ID: 38156444
[TBL] [Abstract] [Full Text] [Related]
3. Management of Brain Metastases: A Review of Novel Therapies.
Bellur S; Khosla AA; Ozair A; Kotecha R; McDermott MW; Ahluwalia MS
Semin Neurol; 2023 Dec; 43(6):845-858. PubMed ID: 38011864
[TBL] [Abstract] [Full Text] [Related]
4. Circulating lung cancer biomarkers: From translational research to clinical practice.
Qian X; Meng QH
Tumour Biol; 2024; 46(s1):S27-S33. PubMed ID: 37927289
[TBL] [Abstract] [Full Text] [Related]
5. KZ02 enhances the radiosensitivity of braf-mutated CRC in vitro and in vivo.
Guo Y; Li X; Yuan R; Ren J; Huang Y; Yu Y; Tian H
Eur J Pharmacol; 2023 Nov; 959():176060. PubMed ID: 37775019
[TBL] [Abstract] [Full Text] [Related]
6. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs.
Choi HY; Chang JE
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686423
[TBL] [Abstract] [Full Text] [Related]
7. braf(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.
Yap J; Yuan J; Ng WH; Chen GB; Sim YRM; Goh KC; Teo J; Lim TYH; Goay SM; Teo JHJ; Lao Z; Lam P; Sabapathy K; Hu J
Mol Cancer; 2023 Aug; 22(1):125. PubMed ID: 37543582
[TBL] [Abstract] [Full Text] [Related]
8. Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi-institutional study.
Liu X; Yue H; Jiang S; Kong L; Xu Y; Chen Y; Wang C; Wang Y; Zhu X; Kong Y; Zhang X; Qian J; Luo Z
Cancer Med; 2023 Aug; 12(15):16163-16172. PubMed ID: 37409486
[TBL] [Abstract] [Full Text] [Related]
9. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.
Berlanga P; Ndounga-Diakou LA; Aerts I; Corradini N; Ducassou S; Strullu M; de Carli E; André N; Entz-Werle N; Raimbault S; Roumy M; Renouard M; Gueguen G; Plantaz D; Reguerre Y; Cleirec M; Petit A; Puiseux C; Andry L; Klein S; Bodet D; Kanold J; Briandet C; Halfon-Domenech C; Nelken B; Piguet C; Saumet L; Chastagner P; Benadiba J; Millot F; Pluchart C; Schneider P; Thouvenin S; Gambart M; Serre J; Abbou S; Leruste A; Cayzac H; Gandemer V; Laghouati S; Vassal G
JAMA Netw Open; 2023 Jul; 6(7):e2321568. PubMed ID: 37399010
[TBL] [Abstract] [Full Text] [Related]
10. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.
Heipertz AE; Pajtler KW; Pfaff E; Schramm K; Blattner-Johnson M; Milde T; Jones BC; Zuliani C; Hutter C; Lohi O; Kattamis A; Dachowska-Kalwak I; Nilsson A; Gerber NU; Langenberg KPS; Goemans B; Zwaan CM; Molenaar JJ; Jäger N; Dirksen U; Witt R; Pfister SM; Jones DTW; Kopp-Schneider A; Witt O; van Tilburg CM
JCO Precis Oncol; 2023 Jun; 7():e2300015. PubMed ID: 37364231
[TBL] [Abstract] [Full Text] [Related]
11. Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With treatment-Naive, Advanced, ALK-Positive NSCLC.
Soo RA; Martini JF; van der Wekken AJ; Teraoka S; Ferrara R; Shaw AT; Shepard D; Calella AM; Polli A; Toffalorio F; Tomasini P; Chiu CH; Kowalski DM; Kim HR; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1568-1580. PubMed ID: 37295609
[TBL] [Abstract] [Full Text] [Related]
12. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
13. Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.
Chi SA; Yu H; Choi YL; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Choi DH; Kim K; Jung HA; Park K
JAMA Netw Open; 2023 Mar; 6(3):e232002. PubMed ID: 36929402
[TBL] [Abstract] [Full Text] [Related]
14. Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry.
Burns EA; Sanchez CG; Mathur S; Guerrero C; Muhsen IN; Sarfraz H; Hu CA; Tang CA; Shah SS; Tremont IW; Teh B; Ganguly S; Pingali SRK
Ann Hematol; 2023 May; 102(5):1111-1120. PubMed ID: 36922432
[TBL] [Abstract] [Full Text] [Related]
15. Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients.
Derenzini E; Gueli A; Risso A; Bruna R; Gottardi D; Cignetti A; Pileri S; Avvedimento EV; Tarella C
Hematol Oncol; 2023 Aug; 41(3):335-342. PubMed ID: 36533316
[TBL] [Abstract] [Full Text] [Related]
16. [Gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
[No Abstract] [Full Text] [Related]
17. Lung adenocarcinoma harboring complex EML4-ALK fusion and braf V600E co-mutation responded to alectinib.
Guo W; Liang J; Zhang D; Huang X; Lv Y
Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356
[TBL] [Abstract] [Full Text] [Related]
18. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.
Soo R; Mery L; Bardot A; Kanesvaran R; Keong TC; Pongnikorn D; Prasongsook N; Hutajulu SH; Irawan C; Manan AA; Thiagarajan M; Sripan P; Peters S; Storm H; Bray F; Stahel R
ESMO Open; 2022 Oct; 7(5):100560. PubMed ID: 35988454
[TBL] [Abstract] [Full Text] [Related]
19. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract] [Full Text] [Related]
20. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
[TBL] [Abstract] [Full Text] [Related]
[Next]
